Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000205

EU PAS number

EUPAS1000000205

Study ID

1000000205

Official title and acronym

Patient characteristics and treatment pathways in patients with asthma or asthma-COPD overlap treated with Medium-Strength ICS/LABA and switching to High-StrEngth ICS/LABA or Medium-Strength TRImbow (BETRI)

DARWIN EU® study

No

Study countries

United Kingdom

Study description

Effects of switching to triple therapy versus escalation of dual therapy regimen in patients with asthma or asthma-COPD overlap treated with medium-strength dual therapy

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

David Price

Primary lead investigator
ORCID number:
0000-0002-9728-9992
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Chiesi Farmaceutici S.p.A.
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable